Isothermal Amplification
-
Freeze-dried Chlamydia Trachomatis
This kit is used for qualitative detection of Chlamydia trachomatis nucleic acid in male urine, male urethral swab, and female cervical swab samples.
-
Mycoplasma Hominis
This kit is used for the qualitative detection of mycoplasma hominis nucleic acid in genitourinary tract samples in vitro.
-
Enterovirus 71 Nucleic Acid
This kit is intended for in vitro qualitative detection of Enterovirus 71 nucleic acid in human throat swab samples.
-
Coxsackie Virus Type A16 Nucleic Acid
This kit is used for in vitro qualitative detection of Coxsackie virus type A16 nucleic acid in human throat swabs.
-
Plasmodium Nucleic Acid
This kit is used for in vitro qualitative detection of malaria parasite nucleic acid in peripheral blood samples of patients suspected of plasmodium infection.
-
Trichomonas Vaginalis Nucleic Acid
This kit is used for the qualitative detection of Trichomonas vaginalis nucleic acid in human urogenital tract secretion samples.
-
Candida Albicans Nucleic Acid
This kit is intended for the in vitro qualitative detection of the nucleic acid of Candida tropicalis in genitourinary tract samples or clinical sputum samples.
-
Mycoplasma Pneumoniae Nucleic Acid
This kit is intended for in vitro qualitative detection of Mycoplasma pneumoniae (MP) nucleic acid in human throat swabs.
-
Human Respiratory Syncytial Virus Nucleic Acid
This kit is used for in vitro qualitative detection of Human respiratory syncytial virus (HRSV) nucleic acid in throat swab samples.
-
Influenza B Virus Nucleic Acid
This kit in intended for in vitro qualitative detection of Influenza B virus nucleic acid in nasopharyngeal and oropharyngeal swab samples.
-
Influenza A Virus Nucleic Acid
The kit is used for qualitative detection of Influenza A virus nucleic acid in human pharyngeal swabs in vitro.
-
Group B Streptococcus Nucleic Acid
This kit is intended for the in vitro qualitative detection of the nucleic acid DNA of group B streptococcus in rectal swab samples, vaginal swab samples or mixed rectal/vaginal swab samples from pregnant women at 35 to 37 gestational weeks with high risk factors and at other gestational weeks with clinical symptoms such as premature rupture of membrane and threatened premature labor.
